GILD Latest Headlines

Hepion ends Phase 2 study for NASH drug due to cash restraints

at seekingalpha.com (Fri, 19-Apr 5:10 PM)

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

at www.benzinga.com (Fri, 19-Apr 9:28 AM)

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)

at www.tipranks.com (Fri, 19-Apr 7:50 AM)

FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk

at seekingalpha.com (Fri, 19-Apr 6:13 AM)

Stifel starts Mirum at buy, cites IBATi drug potential

at seekingalpha.com (Thu, 18-Apr 10:39 AM)

Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns

at www.tipranks.com (Thu, 18-Apr 6:06 AM)

If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today

at www.benzinga.com (Wed, 17-Apr 2:30 PM)